NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Descriptive Observational Study ALK-2016-CPHG

CompletedN/A

Sponsor: Pfizer

Conditions: NSCLC, Crizotinib, ALK Gene Rearrangement or ROS1 Gene Rearrangement

Countries: France

Descriptive Observational Study. Characteristics Of ALK-positive and ROS1-positive Adults Patients Non-Small Cell Lung Cancer (NSCLC) Treated With Crizotinib Within General Hospitals

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion criteria

* Age ≥ 18 years
* Locally advanced or metastatic NSCLC
* Patient ALK gene rearrangement or ROS1 gene rearrangement
* Patient having initiated in the previous 3 months or patient initiating crizotinib treatment regardless of the line of treatment
* Patient followed up by a physician in a hospital pulmonary medicine department
* Subject of reproductive age, using an effective method of contraception
* Patient informed verbally and in writing on the study and having consented to his/her personal data being collected within the scope of the study.

Non-inclusion criteria

* Patient included within the scope of an interventional therapeutic trial
* Patient not presenting with ALK gene rearrangement or ROS1 gene rearrangement
* Patient not available for follow-up throughout the duration of the study
* Patient deemed to be incapable of responding to the study questions for linguistic, cognitive or organisational reasons.

Locations (26)

Aix-en-Provence, France
Amiens, France
Aulnay-sous-Bois, France
Avignon, France
Beauvais, France
Béziers, France
Cannes, France
Chalon-sur-Saône, France
Chambéry, France
Colmar, France
Contamine-sur-Arve, France
Fréjus, France
La Roche-sur-Yon, France
La Roche-sur-Yon, France
Le Mans, France
Longjumeau, France
Marseille, France
Mâcon, France
Mulhouse, France
Nevers, France
Orléans, France
Pringy, France
Saint Pierre La Réunion, France
Thonon-les-Bains, France
Troyes, France
Villefranche-sur-Saône, France